Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-11-10

Clinical Trial Update: A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating SAGE-217 for treatment of adult major depressive disorder has completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SAGE-217 (zuranolone)

Snippet

Sponsor: Biogen | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED | Results posted: 2022-11-10